Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E, Albrecht J, Brunk A, Khan S, Schnürer E, Frey M, Mottok A, Jordán-Garrote AL, Brede C, Beilhack A, Mades A, Tomsitz D, Theobald M, Herr W, Hartwig UF.
Distler E, et al.
Int J Cancer. 2016 Mar 1;138(5):1256-68. doi: 10.1002/ijc.29854. Epub 2015 Oct 5.
Int J Cancer. 2016.
PMID: 26376181